In an interview with ACT senior editor Andy Studna at SCOPE Summit, Jonathan Norman, director, localization services, YPrime, discusses the importance of communicating with patients in their native ...
As clinical trial complexity, duration, and cost continue to rise, life sciences companies are turning to data to help them ...
Nevertheless, there is no question that the research credit provides significant tax savings and should be considered by ...
Based on our research, we estimate that the global investigative site community spent $170 million in 2024 to complete ...
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, chief strategy officer, Cluepoints, ...
Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...
The art of saying no in clinical trials goes beyond simply delivering news; it involves maintaining relationships and ...
The conundrum of missing data vs. inter-rater variability.
Tips and best practices for empowering professionals to become change agents in their institutions, including clinical trials ...
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Peter Ronco, CEO, Emmes, provides advice to small biopharma companies looking to scale their clinical programs without ...
In an interview with Applied Clinical Trials Associate Editor Don Tracy, Richard Young, CEO, CluePoints, discusses goals of the SCOPE Summit and CluePoints' evolving approach to risk detection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback